Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1

Journal of Medicinal Chemistry

Volumn 53, Issue 9, 2010, Pages 3502-3516

  Goodnow, Robert A ^a   Hicks, Alexandra ^b   Sidduri, Achyutharao ^a   Kowalczyk, Agnieszka ^a   Dominique, Romyr ^a   Qiao, Qi ^a   Lou, Jian Ping ^a   Gillespie, Paul ^a   Fotouhi, Nader ^a   Tilley, Jefferson ^a   Cohen, Noal ^a   Choudhry, Satish ^c   Cavallo, Gary ^b   Tannu, Shahid A ^b   Ventre, Jessica D ^b   Lavelle, Danielle ^b   Tare, Nadine S ^b   Oh, Hyesun ^d   Lamb, Martin ^d   Kurylko, Grazyna ^e   Hamid, Rachid ^e   Wright, Matthew B ^e   Pamidimukkala, Anjula ^d   Egan, Thomas ^d   Gubler, Ueli ^e   Hoffman, Ann F ^e   Wei, Xin ^f   Li, Ying L ^f   O'Neil, John ^g   Marcano, Ruben ^g   Pozzani, Karen ^g   Molinaro, Tina ^g   Santiago, Jennifer ^g   Singer, Laura ^g   Hargaden, Maureen ^g   Moore, David ^d   Catala, A Robert ^d   Chao, Lisa C F ^h   Hermann, Gesine ⁱ   Venkat, Radhika ^j   Mancebo, Helena ^j   Renzetti, Louis M ^b   more..

^a Discovery Chemistry   (United States)

^b Roche   (United States)

^c Chemical Synthesis   (United States)

^d Non Clinical Safety   (United States)

^e Discovery Technologies   (United States)

^f In Silico Sciences   (United States)

^g Laboratory Animal Resources   (United States)

^h HOFFMANN LA ROCHE INC   (United States)

ⁱ ChemOvation Ltd   (United Kingdom)

^j Multispan Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

1 IODO 3 METHOXY 5 NITROBENZENE; 2 (3 BENZYL 4 HYDROXYCHROMAN 7 YL) 4 TRIFLUOROMETHYLBENZOIC ACID; 3 (3 METHOXY 5 NITROPHENYL)THIOPHENE; 4 (2 FORMYL 3 METHYLPHENOXY)BUTYRIC ACID ETHYL ESTER; 4 (2,3 DIMETHYLPHENOXY)BUTYRIC ACID ETHYL ESTER; 4 [2 (2 CARBOXYETHYL) 3 [6 (3,5 DIBROMOPHENOXY)HEXYL]PHENOXY]BUTYRIC ACID; 4 [2 (2 CARBOXYETHYL) 3 [6 (3,5 DIPYRIMIDIN 5 YLPHENOXY)HEXYL]PHENOXY]BUTYRIC ACID; 4 [2 (2 CARBOXYETHYL) 3 [6 (5 THIOPHEN 3 YLBIPHENYL 3 YLOXY)HEXYL]PHENOXY]BUTYRIC ACID; 4 [2 (2 CARBOXYETHYL) 3 [6 ([1,1',3,1'']TERPHENYL 5' YLOXY)HEXYL]PHENOXY]BUTYRIC ACID; 4 [2 (2 CARBOXYETHYL) 3 [6 ([1,10,3,1'']TERPHENYL 5' YLOXY)HEXYL]PHENOXY]BUTYRIC ACID; 4 [2 (2 ETHOXYCARBONYLETHYL) 3 (6 HYDROXYHEXYL)PHENOXY]BUTYRIC ACID ETHYL ESTER; 4 [2 (2 ETHOXYCARBONYLETHYL) 3 [6 ([1,1',3,1'']TERPHENYL 5' YLOXY)HEXYL]PHENOXY]BUTYRIC ACID ETHYL ESTER; 4 [2 (2 ETHOXYCARBONYLVINYL) 3 METHYLPHENOXY]BUTYRIC ACID ETHYL ESTER; 4 [3 (6 BROMOHEXYL) 2 (2 ETHOXYCARBONYLETHYL)PHENOXY]BUTYRIC ACID ETHYL ESTER; 4 [3 [6 (3,5 DIBROMOPHENOXY)HEXYL] 2 (2 ETHOXYCARBONYLETHYL)PHENOXY]BUTYRIC ACID ETHYL ESTER; 4 [3 [6 (TERT BUTYLDIMETHYLSILANYLOXY)HEX 1 ENYL] 2 (2 ETHOXYCARBONYLVINYL)PHENOXY]BUTYRIC ACID ETHYL ESTER; 4 [3 [6 (TERT BUTYLDIMETHYLSILANYLOXY)HEXYL] 2 (2 ETHOXYCARBONYLETHYL)PHENOXY]BUTYRIC ACID ETHYL ESTER; 4 [3 BROMOMETHYL 2 (2 ETHOXYCARBONYLVINYL)PHENOXY]BUTYRIC ACID ETHYL ESTER; 5 (TERT BUTYLDIMETHYLSILANYLOXY)PENTANAL; 5 ETHYL 2 HYDROXY 4 [6 METHYL 6 (1H TETRAZOL 5 YL)HEPTYLOXY]ACETOPHENONE; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; AMELUBANT; ANTIINFLAMMATORY AGENT; BIIL 284; CARBINOXAMINE; DW 1350; ETALOCIB; G PROTEIN COUPLED RECEPTOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MOXILUBANT MALEATE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MODEL; FEMALE; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HL-60 CELLS; HUMANS; LEUKOTRIENE ANTAGONISTS; PHENYL ETHERS; PRIMATES; PROTEIN BINDING; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LEUKOTRIENE B4; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952062114     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1001919     Document Type: Article

References (35)

1. Kim, N. D.; Luster, A. D. Regulation of immune cells by eicosanoid receptors Sci. World J. 2007, 7, 1307-1328
2. 4 receptors BLT1 and BLT2: expression and function in human and murine mast cells J. Immunol. 2006, 177, 3439-3447
3. 4 receptor Am. J. Respir. Cell Mol. Biol. 2010, 42, 294-303
4. 4 in acute respiratory distress syndrome Respir. Care 2007, 52, 1695-1700
5. Hlawaty, H.; Jacob, M.-P.; Louedec, L.; Letourneur, D.; Brink, C.; Michel, J.-B.; Feldman, L.; Bäck, M. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis Arterioscler., Thromb., Vasc. Biol 2009, 29, 518-524
6. 4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments Expert Opin. Invest. Drugs 2007, 16, 1909-1920
7. 4 receptor antagonists: recent clinical developments Expert Opin. Invest. Drugs 1996, 5, 73-77
8. 4 receptor antagonist J. Pharmacol. Exp. Ther. 2001, 297, 458-466
9. IDdb3 Drug Alerts; Thomson Scientific Ltd.: Philadelphia, PA, 1997-2007.
10. 4 antagonist CP-195543 J. Pharmacol. Exp. Ther. 1998, 285, 946-954
11. Saif, M. W.; Oettle, H.; Vervenne, W. L.; Thomas, J. P.; Spitzer, G.; Visseren-Grul, C.; Enas, N.; Richards, D. A. Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas Cancer J. 2009, 15, 339-343
12. Janne, P. A.; Paz-Ares Rodriguez, L.; Gottfried, M.; Reaume, M. N.; Kaukel, T.; Oh, Y. W.; Sykes, A.; Enas, N.; Brail, L. H.; Von Pawel, J. Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosonaid pathway modulator, in patients with chemotherapy naive advanced non-small cell lung carcinoma J. Clin. Oncol. 2006, 24 (18, Suppl.) 7024
13. Clinical Trials Web Site. Study Identifier: NCT00493974 (2007). http://www.clinicaltrials.gov.
14. 4 Antagonists. PCT Int. Appl. WO 9528386 A1, 1995; 73 pp.
15. Unpublished results.
16. Detailed experimental procedures for compounds in this manuscript and others are also described in WO 2009024492 A1.
17. Daniewski, A. R.; Radinov, R. N. Process for Preparing CD Ring Fragment of Vitamin D3 an Anti-Osteoporotic Agent. EP 1048661, 2000; 16 pp.
18. Rathke, M. W.; Nowak, M. The Horner-Wadsworth-Emmons modification of the Wittig reaction using triethylamine and lithium or magnesium salts J. Org. Chem. 1985, 50, 2624-2626
19. Suzuki, A. The Suzuki Reaction with Arylboron Compounds in Arene Chemistry. In Modern Arene Chemistry, 1 st ed.; Astruc, D., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2002; pp 53-106.
20. Reich, S. H.; Johnson, T.; Wallace, M. B.; Kephart, S. E.; Fuhrman, S. A.; Worland, S. T.; Matthews, D. A.; Hendrickson, T. F.; Chan, F.; Meador, J., III; Ferre, R. A.; Brown, E. L.; DeLisle, D. M.; Patick, A. K.; Binford, S. L.; Ford, C. E. Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis and biological evaluation J. Med. Chem. 2000, 43, 1670-1683
21. Yokomizo, T; Kato, K; Hagiya, H; Izumi, T; Shimizu, T. J. Hydroxyeicosanoids bind to and activate the low affinity leukotriene B4 receptor, BLT2 Biol Chem. 2001, 276, 12454-12459
22. Assay performed at Multispan, Inc. (Hayward, CA, www.multispaninc.com) according to a method described in the Experimental Section.
23. clogP lipophilicities were calculated with ACD Labs software: http://www.acdlabs.com.
24. Fischer, H.; Kansy, M.; Wagner, B. Determination of High Lipophilicity Values U.S. Pat. Appl. Publ. US 2006211121 A1, 2006; 16 pp.
25. Alsenz, J.; Kansy, M. High throughput solubility measurement in drug discovery and development Adv. Drug Delivery Rev. 2007, 59, 546-567
26. Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 1998, 15, 698-705
27. hERG liabilities were assessed using an automated electrophysiology PatchXpress 7000A according to methods as reported in the following: Guo, L.; Guthrie, H. Automated electrophysiology in the preclinical evaluation of drugs for protential QT prolongation J. Pharmacol. Toxicaol. Methods 2005, 52, 123-135
28. Crespi, C. L.; Miller, V. P.; Stresser, D. M. Design and application of fluorometric assays for human cytochrome P450 inhibition Methods Enzymol. 2002, 357, 276-284
29. Walsky, R. L.; Obach, R. S. Validated assays for human cytochrome p450 activities Drug Metab. Dispos. 2004, 32, 647-660
30. Hicks, A.; Goodnow, R. Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates. Prostaglandins and Other Lipid Mediators, in press.
31. Kramer, J. A. Designing safe drugs: what to consider? Expert Opin. Drug Discov. 2008, 3, 707-713
32. Johnson, W. W. Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance Drug Metab. Rev. 2008, 40, 101-147
33. Kamienski, F. X.; Casida, J. E. Importance of demethylenation in the metabolism in vivo and in vitro of methylenedioxyphenyl synergists and related compounds in mammals Biochem. Pharmacol. 1970, 19, 91-112
34. Baldessarini, R. J.; Neumeyer, J. L.; Campbell, A.; Sperk, G.; Ram, V. J.; Arana, G. W.; Kula, N. S. An orally effective, long-acting dopaminergic prodrug: (-)-10,11-methylenedioxy- N -propylnoraporphine Eur. J. Pharmacol. 1982, 77, 87-88
35. The preparation of this compound has also been reported: Takematsu, T.; Nishimura, K.; Sekioka, H.; Sakata, M.; Kawaguchi, Y.; Takamura, S. Dimethylphenoxybutyerate and dimethylphenoxyvalerate herbicides. Jpn. Kokai Tokkyo Koho 1979, 5 pp; JP 54023125 (A).